Pharmacological management of childhood and adolescent anxiety disorders

Anxiety Disorders in Children and Adolescents, Second edition

Volumn , Issue , 2011, Pages 367-391

  Pelligrino, Laurel ^a   Pierce, Courtney ^a   Walkup, John T ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902368342     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511994920.018     Document Type: Chapter

References (81)

1. American Academy of Child and Adolescent Psychiatry (2009). Practice parameter on the use of psychotropic medication in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 961–973. doi: 10.1097/CHI.0b013e3181ae0a0800004583–200909000-00017[pii]
2. Arabgol, F., Panaghi, L., & Hebrani, P. (2009). Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder. European Child and Adolescent Psychiatry, 18, 53–59. doi: 10.1007/s00787–008-0705–9
3. Armitage, R. (2000). The effects of antidepressants on sleep in patients with depression. Canadian Journal of Psychiatry, 45, 803–809.
4. Barnett, S. & Riddle, M. A. (2003). Anxiolytics: benzodiazepines, buspirone, and others. In: A. Martin, L. Scahill, D. S. Charney, & J. F. Leckman (eds.) Pediatric Psychopharmacology: Principles and Practice, pp. 341–351. New York: Oxford University Press.
5. Beidel, D. C., Turner, S. M., Sallee, F. R., Ammerman, R. T., Crosby, L. A., & Pathak, S. (2007). SET-C versus fluoxetine in the treatment of childhood social phobia. Journal of American Academy of Child and Adolescent Psychiatry, 46, 1622–1632.
6. Benjamin, R. S., Costello, E. J., & Warren, M. (1990). Anxiety disorders in a pediatric sample. Journal of Anxiety Disorders, 4, 293–316.
7. Bernstein, G. A., Borchardt, C.M., Perwien, A. R., Crosby, R. D., Kushner, M. G., Thuras, P. D., et al. (2000). Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 276–283.
8. Bernstein, G. A., Garfinkel, B. D., & Borchardt, C. M. (1990). Comparative studies of pharmacotherapy for school refusal. Journal of the American Academy of Child and Adolescent Psychiatry, 29, 773–781.
9. Birmaher, B., Axelson, D. A., Monk, K., Kalas, C., Clark, D. B., Ehmann, M., et al. (2003). Fluoxetine for the treatment of childhood anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 415–423.
10. Birmaher, B., Brent, D. A., Chiappetta, L., Bridge, J., Monga, S., & Baugher, M. (1999). Psychometric properties of the Screen for Child Anxiety Related Emotional Disorders (SCARED): a replication study. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 1230–1236.
11. Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., et al. (2007). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. Journal of the American Medical Association, 297, 1683–1696.
12. Brown, A. M., Deacon, B. J., Abramowitz, J. S., Dammann, J., & Whiteside, S. P. (2007). Parents’ perceptions of pharmacological and cognitive-behavioral treatments for childhood anxiety disorders. Behaviour Research and Therapy, 45, 819–828. doi: S0005–7967(06)00101-X [pii] 10.1016/j.brat.2006.04.010
13. Chiu, S. & Leonard, H. (2003). Antidepressant 1: selective serotonin reuptake inhibitors. In: A. Martin, L. Scahill, D. S. Charney, & J. F. Leckman (eds.) Pediatric Psychopharmacology: Principles and Practice, pp. 274–283. New York: Oxford University Press.
14. Cook, E. H., Wagner, K. D., March, J. S., Biederman, J., Landau, P., Wolkow, R., et al. (2001). Long-termsertraline treatment of children and adolescents with obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 1175–1181.
15. DeVeaugh-Geiss, J., Moroz, G., Biederman, J., Cantwell, D., Fontaine, R., Greist, J. H., et al. (1992). Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: a multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 45–49.
16. Donnelly, C. L. (2003). Pharmacologic treatment approaches for children and adolescents with posttraumatic stress disorder. Child and Adolescent Psychiatric Clinics of North America, 12, 251–269.
17. Fairbanks, J. M., Pine, D. S., Tancer, N. K., Dummit, E. S., III, Kentgen, L. M., Martin, J., et al. (1997). Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 7, 17–29.
18. Famularo, R., Kinscherff, R., & Fenton, T. (1988). Propranolol treatment for childhood posttraumatic stress disorder, acute type: a pilot study. American Journal of Diseases of Children, 142, 1244–1247.
19. Garland, E. J., & Baerg, E. A. (2001). Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 11, 181–186.
20. Garner, E. M., Kelly, M. W., & Thompson, D. F. (1993). Tricyclic antidepressant withdrawal syndrome. Annals of Pharmacotherapy, 27, 1068–1072.
21. Geller, D. A., Biederman, J., Stewart, S. E., Mullin, B., Farrell, C., Wagner, K. D., et al. (2003). Impact of comorbidity on treatment response to paroxetine in pediatric obsessivecompulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? Journal of Child and Adolescent Psychopharmacology, 13(Suppl. 1), S19–S29. doi: 10.1089/104454603322126313
22. Geller, D., Donnelly, C., Lopez, F., Rubin, R., Newcorn, J., Sutton, V., et al. (2007). Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1119–1127. doi: 10.1097/chi.0b013e3180ca8385S0890–8567(09)61930–4[pii]
23. Geller, D. A., Hoog, S. L., Heiligenstein, J. H., Ricardi, R. K., Tamura, R., Kluszynski, S., et al. (2001). Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 773–779.
24. Geller, D. A., Wagner, K. D., Emslie, G., Murphy, T., Carpenter, D. J., Wetherhold, E., et al. (2004). Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 1387–1396.
25. Gibbons, R. D., Hur, K., Bhaumik, D. K., & Mann, J. J. (2005). The relationship between antidepressant medication use and rate of suicide. Archives of General Psychiatry, 62, 165–172.
26. Gittelman-Klein, R. & Klein, D. (1971). Controlled imipramine treatment of school phobia. Archives of General Psychiatry, 25, 204.
27. Graae, F., Milner, J., Rizzotto, L., & Klein, R. G. (1994). Clonazepam in childhood anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 372–376.
28. Greene, D. S., Salazar, D. E., Dockens, R. C., Kroboth, P., & Barbhaiya, R. H. (1995). Coadministration of nefazodone and benzodiazepines. III. A pharmacokinetic interaction study with alprazolam. Journal of Clinical Psychopharmacology, 15, 399–408.
29. Guy, W. (1976). The clinical global impression scale. In: The ECDEU Assessment Manual for Psychopharmacology – Revised, Vol. DHEW Publ. No. ADM 76–338, pp. 218–222. Rockville, MD: US Department of Health, Education, and Welfare Public Health Service, Alcohol, Drug Abuse, Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research.
30. Hammad, T. (2004). Review and evaluation of clinical data: relationship between psychotropic drugs and pediatric suicidality. Available at www.fda.gov/ohrms/dockets/ac/04/briefing/2004–4065b1–10-TAB08-Hammads-Review.pdf.
31. Hammad, T. A., Laughren, T., & Racoosin, J. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63, 332–339.
32. Harmon, R. J. & Riggs, P. D. (1996). Clonidine for posttraumatic stress disorder in preschool children. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1247–1249. doi: S0890–8567(09)63499–7[pii]10.1097/00004583–199609000-00022
33. Hoehn-Saric, R., Harris, G. J., Pearlson, G. D., Cox, C. S., Machlin, S. R., & Camargo, E. E. (1991). A fluoxetine-induced frontal lobe syndrome in an obsessive compulsive patient. Journal of Clinical Psychiatry, 52, 131–133.
34. Horrigan, J. P. & Barnhill, L. J. (1999). Risperidone and PTSD in boys. Journal of Neuropsychiatry and Clinical Neurosciences, 11, 126–127.
35. Ipser, J. C., Stein, D. J., Hawkridge, S., & Hoppe, L. (2009). Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database of Systematic Reviews, 3, CD005170. doi: 10.1002/14651858.CD005170.pub2
36. Jayaram, G. & Rao, P. (2005). Safety of trazodone as a sleep agent for inpatients. Psychosomatics, 46, 367–369. doi: 46/4/367[pii]10.1176/appi.psy.46.4.367
37. Kaufman, J., Birmaher, B., Brent, D., Rao, U., Flynn, C., Moreci, P., et al. (1997). Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 980–988.
38. Klein, R. G., Koplewicz, H. S., & Kanner, A. (1992). Imipramine treatment of children with separation anxiety disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 21–28.
39. Labellarte, M. J., Ginsburg, G. S., Walkup, J. T., & Riddle, M. A. (1999). The treatment of anxiety disorders in children and adolescents. Biological Psychiatry, 46, 1567–1578. doi: S0006–3223(99)00248–6[pii]
40. Lavori, P.W. & Dawson, R. (2004). Dynamic treatment regimes: practical design considerations. Clinical Trials, 1, 9–20.
41. Leonard, H. L., Goldberger, E. L., Rapoport, J. L., Cheslow, D. L., & Swedo, S. E. (1990). Childhood rituals: normal development or obsessive-compulsive symptoms? Journal of the American Academy of Child and Adolescent Psychiatry, 29, 17–23. doi: S0890–8567(09)65104–2[pii]10.1097/00004583–199001000-00004
42. Levine, S. (1967).Maternal and environmental influences on the adrenocortical response to stress in weanling rats. Science, 156, 258–260.
43. Levine, S., & Mullins, R. F., Jr. (1966). Hormonal influences on brain organization in infant rats. Science, 152, 1585–1592.
44. Looff, D., Grimley, P., Kuller, F., Martin, A., & Shonfield, L. (1995). Carbamazepine for PTSD. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 703–704. doi: S0890– 8567(09)63566–8[pii]10.1097/00004583–199506000-00008
45. March, J. S., Biederman, J., Wolkow, R., Safferman, A., Mardekian, J., Cook, E. H., et al. (1998). Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. Journal of the American Medical Association, 280, 1752–1756.
46. March, J. S., Entusah, A. R., Rynn, M., Albano, A. M., & Tourian, K. A. (2007). A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biological Psychiatry, 62, 1149–1154.
47. March, J. S., Parker, J.D., Sullivan, K., Stallings, P., & Conners, C.K. (1997).TheMultidimensional Anxiety Scale for Children (MASC): factor structure, reliability, and validity. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 554–565.
48. Martin-Du, P. R. & Baumann, P. (2008). Sexual dysfunctions induced by antidepressants and antipsychotics. Revue Medicale Suisse, 4, 758–762.
49. McDougle, C. J., Epperson, C.N., Pelton, G.H., Wasylink, S., & Price, L.H. (2000).Adouble-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Archives of General Psychiatry, 57, 794–801.
50. Montgomery, S. A. (1998). Chairman's overview: The place of reboxetine in antidepressant therapy. Journal of Clinical Psychiatry, 59(Suppl. 14), 26–29.
51. Norrholm, S. D. & Ouimet, C. C. (2001). Altered dendritic spine density in animal models of depression and in response to antidepressant treatment. Synapse, 42, 151–163.
52. Papakostas, G. I., Stahl, S. M., Krishen, A., Seifert, C. A., Tucker, V. L., Goodale, E. P., et al. (2008). Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. Journal of Clinical Psychiatry, 69, 1287–1292. doi: ej07m03773[pii]
53. Pine, D. S. (2002). Treating children and adolescents with selective serotonin reuptake inhibitors: how long is appropriate? Journal of Child and Adolescent Psychopharmacology, 12, 189–203.
54. Pediatric OCD Treatment Study (2004). Cognitive–behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. Journal of the American Medical Association, 292, 1969–1976.
55. Preskorn, S. H. (2000). Imipramine, mirtazapine, and nefazodone: multiple targets. Journal of Practical Psychiatry and Behavioral Health, March, 97–102.
56. Reinblatt, S. P., dosReis, S., Walkup, J. T., & Riddle, M. A. (2009). Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 19, 119–126. doi: 10.1089/cap.2008.040
57. Reinblatt, S. P. & Walkup, J. T. (2005). Psychopharmacologic treatment of pediatric anxiety disorders. Child and Adolescent Psychiatric Clinics of North America, 14, 877–908.
58. Reiter, S. & Kutcher, S. P. (1991). Disinhibition and anger outbursts in adolescents treated with clonazepam. Journal of Clinical Psychopharmacology, 11, 268.
59. Riddle, M.A., Bernstein, G. A., Cook, E. H., Leonard, H. L., March, J. S., & Swanson, J.M. (1999). Anxiolytics, adrenergic agents, and naltrexone. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 546–556.
60. Riddle, M. A., Geller, B., & Ryan, N. (1993). Another sudden death in a child treated with desipramine. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 792–797.
61. Riddle, M. A., Reeve, E. A., Yaryura-Tobias, J. A., Yang, H. M., Claghorn, J. L., Gaffney, G., et al. (2001). Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 222–229.
62. Robert, R., Blakeney, P. E., Villarreal, C., Rosenberg, L., & Meyer, W. J., III (1999). Imipramine treatment in pediatric burn patients with symptoms of acute stress disorder: a pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 873–882. doi: S0890–8567(09)66537–0[pii]10.1097/00004583–199907000-00018
63. Rotzinger, S., Fang, J., & Baker, G. B. (1998). Trazodone is metabolized to mchlorophenylpiperazine by CYP3A4 from human sources. Drug Metabolism and Disposition, 26, 572–575.
64. Rotzinger, S., Fang, J., Coutts, R. T., & Baker, G. B. (1998). Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biological Psychiatry, 44, 1185–1191. doi: S0006–3223(97)00483–6[pii]
65. Research Unit on Pediatric Psychopharmacology (2001). Fluvoxamine for the treatment of anxiety disorders in children and adolescents: the Research Unit on Pediatric Psychopharmacology Anxiety Study Group. New England Journal of Medicine, 344, 1279–1285.
66. ResearchUnit on Pediatric Psychopharmacology (RUPP) (2002). Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study. Journal of Child and Adolescent Psychopharmacology, 12, 175–188.
67. Rynn, M. A., Riddle, M. A., Yeung, P. P., & Kunz, N. R. (2007). Efficacy and safety of extendedrelease venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. American Journal of Psychiatry, 164, 290–300.
68. Safer, D. J. & Zito, J. M. (2006). Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. Journal of Child and Adolescent Psychopharmacology, 16, 159–169. doi: 10.1089/cap.2006.16.159
69. Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., Goodman, W. K., et al. (1997). Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 844–852.
70. Scharko, A. M. (2004). Selective serotonin reuptake inhibitor-induced sexual dysfunction in adolescents: a review. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 1071–1079. doi: S0890–8567(09)61441–6[pii]10.1097/01.chi.0000131135.70992.58
71. Seedat, S., Stein, D. J., Ziervogel, C., Middleton, T., Kaminer, D., Emsley, R. A., et al. (2002). Comparison of response to a selective serotonin reuptake inhibitor in children, adolescents, and adults with posttraumatic stress disorder. Journal of Child and Adolescent Psychopharmacology, 12, 37–46.
72. Shaffer, D., Fisher, P., Dulcan, M. K., & Davies, M. (1996). The NIMH Diagnostic Interview Schedule for Children Version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA study. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 865–877.
73. Silverman, W. K. & Albano, A. M. (1994). The Anxiety Disorders Interview Schedule for DSMIV: Research and Lifetime Version for Children and Parents (ADIS-RLV). New York: Columbia University.
74. Simeon, J. G. & Ferguson, H. B. (1987). Alprazolam effects in children with anxiety disorders. Canadian Journal of Psychiatry, 32, 570–574.
75. Spencer, T., Biederman, J., Coffey, B., Geller, D., Crawford, M., Bearman, S. K., et al. (2002). A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 59, 649–656.
76. Velosa, J. F. & Riddle, M. A. (2000). Pharmacologic treatment of anxiety disorders in children and adolescents. Child and Adolescent Psychiatric Clinics of North America, 9, 119–133.
77. Wagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J., Perera, P., et al. (2004). Amulticenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Archives of General Psychiatry, 61, 1153–1162.
78. Walkup, J. & Labellarte, M. (2001). Complications of SSRI treatment. Journal of Child and Adolescent Psychopharmacology, 11, 1–4.
79. Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., et al. (2008). Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. New England Journal of Medicine, 359, 2753–2766.
80. Wegerer, V., Moll, G. H., Bagli, M., Rothenberger, A., Ruther, E., & Huether, G. (1999). Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. Journal of Child and Adolescent Psychopharmacology, 9, 13–24
81. Wilens, T. E., Biederman, J., Baldessarini, R. J., Geller, B., Schleifer, D., Spencer, T. J., et al. (1996). Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1491–1501.